Literature DB >> 7679333

Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium.

P Molenaar1, G O'Reilly, A Sharkey, R E Kuc, D P Harding, C Plumpton, G A Gresham, A P Davenport.   

Abstract

The characterization and localization of endothelin A (ETA) and endothelin B (ETB) receptors have been determined in tissue sections of the human atrioventricular conducting system, surrounding regions of atrial and ventricular myocardium, and the left ventricular free wall by use of radioligand binding, polymerase chain reaction, and in situ hybridization. Selective ETA (BQ123) and ETB (BQ3020) compounds in conjunction with [125I]endothelin-1 revealed the presence of ETA and ETB receptors in the left ventricular free wall (BQ123: 57 +/- 5% ETA, 43 +/- 2% ETB, n = 3; BQ3020: 67 +/- 3% ETA, 33 +/- 3% ETB, n = 3). Autoradiography using [125I]endothelin-1 in the absence or presence of BQ3020, BQ123, or endothelin-1 showed ETA and ETB receptors localized to atrial and ventricular myocardium, the atrioventricular conducting system, and endocardial cells. There was a higher proportion of ETB receptors in the atrioventricular node and the penetrating and branching bundles of His than in the surrounding interventricular and interatrial septa (p < 0.0001). There was a lower density of ETB receptors in the interventricular septum compared with the interatrial septum and the atrioventricular conducting system (p = 0.009) and a lower density of ETA receptors in the atrioventricular conducting system compared with interatrial and interventricular septa (p = 0.008). Isolated right atrial myocytes showed a higher proportion of ETA receptors (91 +/- 12%, n = 3). Amplification of left ventricular free wall cDNA by polymerase chain reaction revealed the presence of ETA and ETB receptor mRNA. mRNA for both subtypes was detected in isolated atrial myocytes. In situ hybridization showed ETA and ETB receptor mRNA localization to atrial and ventricular myocardium, the atrioventricular conducting system, and endocardial cells. These studies demonstrate the presence of ETA and ETB receptors in human myocardium and the atrioventricular conducting system.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7679333     DOI: 10.1161/01.res.72.3.526

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  56 in total

Review 1.  Do endothelin receptor antagonists have an antiarrhythmic potential during acute myocardial infarction? Evidence from experimental studies.

Authors:  Dimitrios L Oikonomidis; Giannis G Baltogiannis; Theofilos M Kolettis
Journal:  J Interv Card Electrophysiol       Date:  2010-06-08       Impact factor: 1.900

2.  Characterization of the binding of endothelin ETB selective ligands in human and rat heart.

Authors:  F D Russell; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

3.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

Review 4.  Regulation of blood pressure and salt homeostasis by endothelin.

Authors:  Donald E Kohan; Noreen F Rossi; Edward W Inscho; David M Pollock
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

5.  Differential distribution of endothelin peptides and receptors in human adrenal gland.

Authors:  A P Davenport; S L Hoskins; R E Kuc; C Plumpton
Journal:  Histochem J       Date:  1996-11

6.  Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system.

Authors:  K E Wiley; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

7.  Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart.

Authors:  M G Peter; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

8.  Endothelin receptors in human coronary artery and aorta.

Authors:  C R Bacon; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 9.  Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.

Authors:  Navneet S Rehsia; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

10.  Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes.

Authors:  Nikolaos Ostlund Papadogeorgos; Mattias Bengtsson; Majid Kalani
Journal:  Vasc Health Risk Manag       Date:  2009-11-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.